TXG Earnings Prediction
The chart below shows how TXG performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TXG sees a +3.07% change in stock price 10 days leading up to the earnings, and a +2.60% change 10 days following the report. On the earnings day itself, the stock moves by +2.13%. This data can give you a slight idea of what to expect for the next quarter's release.
TXG Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
165.02M
-10.30%
8.81%
Gross Margin
67.24%
6.85%
-4.16%
Operating Margin
-30.20%
91.50%
10.38%
Net Margin
-29.71%
11.65%
26.00%
EPS
-0.40
-2.44%
33.33%
No Data Available
TXG Earnings Analysis
10X Genomics Inc Corporation (TXG.O) Earnings Conference Call
Positive
Fourth Quarter Revenue Increase: Total revenue for the fourth quarter was $165,000,000, an increase of 9% sequentially, indicating strong performance despite a year-over-year decrease.
Spatial Product Revenue Growth: Spatial product revenue grew 33% year over year, highlighting the increasing demand and success of the spatial platforms.
Services Revenue Surge: Services revenue increased by 35% to $7,100,000 in the fourth quarter, reflecting a growing reliance on service offerings by customers.
Gross Margin Improvement: Gross margin improved to 67% in the fourth quarter, up from 63% in the prior year, driven by a favorable change in product mix.
Operating Expenses Reduction: Total operating expenses decreased to $160,800,000 in the fourth quarter, down from $171,000,000 in the prior year, demonstrating effective cost management.
Negative
Revenue Decline Analysis: Total revenue for 2024 was $611,000,000, down 1% compared to the prior year, indicating a stagnation in growth amidst a challenging macro environment.
Chromium Revenue Decline: Chromium consumables revenue decreased by 11% to $372,300,000 for the full year, reflecting a significant decline in demand for this key product line.
Decline in Instrument Revenue: Total instrument revenue fell by 25% to $92,700,000, with spatial instrument revenue down 24%, highlighting a substantial drop in sales across the board.
Americas Revenue Decline: Americas revenue decreased by 7% to $347,800,000, suggesting a weakening market presence in a critical region for the company.
Projected Revenue Decline: The company anticipates a mid single-digit decrease in NIH funded projects for 2025, which could result in a $7,000,000 impact on revenue, compounded by potential indirect funding cuts that could further reduce revenue by $10,000,000 to $15,000,000.
TXG FAQs
How does TXG typically perform around its earnings report dates?
Is 10X Genomics Inc (TXG) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TXG Earning Call Sentiment
Earnings call transcript: 10X Genomics Q4 2024 misses EPS forecast, stock dips
TXG.O
4.42%Positive
The earnings call presents a mixed but overall negative outlook. Revenue declines in key segments and flat guidance, coupled with uncertainties around NIH funding cuts, suggest challenges ahead. Despite some positive aspects like improved gross margins and cost management, the lack of a shareholder return plan and unclear management responses in the Q&A raise concerns. The market cap indicates moderate sensitivity, but the negative elements outweigh positives, leading to a predicted stock price decline.
